# A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma

> **NCT06695026** · PHASE1,PHASE2 · RECRUITING · sponsor: **Rznomics, Inc.** · enrollment: 45 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** RZ-001 Dose 1
- **DRUG:** RZ-001 Dose 2
- **DRUG:** RZ-001 Dose 3

## Key facts

- **NCT ID:** NCT06695026
- **Lead sponsor:** Rznomics, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-18
- **Primary completion:** 2027-08
- **Final completion:** 2027-10
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06695026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06695026, "A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06695026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*